Results of a world-first phase 3 trial for secondary progressive multiple sclerosis (MS), led by UCL researchers, have shown that the commonly used high-cholesterol drug simvastatin cannot slow disability progression.
Clinical trial: Cholesterol drug ineffective for treatment of multiple sclerosis retrieved 24 September 2024 from https://medicalxpress.com/news/2024-09-clinical-trial-cholesterol-drug-ineffective.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
Medicine Research Health Research News Health Research Health Science Medicine Science
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Researchers announce clinical trial results for hard-to-treat breast and bladder cancersProfessors Tom Powles and Peter Schmid recently delivered results from their phase three clinical trials during Sunday's Presidential Symposium to over 30,000 attendees at the European Society for Medical Oncology (ESMO) Congress 2024.
Read more »
Team publishes results from clinical trial evaluating cabozantinib in advanced neuroendocrine tumorsThe Alliance for Clinical Trials in Oncology today announced that final results will be presented at ESMO 2024 from CABINET (A021602), a phase III trial evaluating cabozantinib compared with placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort of patients with advanced pancreatic neuroendocrine tumors (pNET)...
Read more »
Clinical trial: Combining durvalumab with novel agents increases pathological responses in resectable NSCLCPhase 2 results from the NeoCOAST-2 study have demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete response rates among the tested regimens.
Read more »
Heart drug improves exercise tolerance in clinical trial of patients with hypertrophic obstructive cardiomyopathyExercise intolerance is often severe among patients with cardiovascular disease and can impose significant limitations on their physical abilities and quality of life.
Read more »
Clinical trial assesses the efficacy of suvorexant in reducing delirium in older adultsDelirium is a sudden onset and temporary state of disturbed consciousness or cognition, occurring due to underlying medical issues like fever or alcohol withdrawal. It is most common among older hospitalized adults aged 75 years or above, leading to increased risk of falls, dementia, low life expectancy, and high health care expenses.
Read more »
Researchers attempt to emulate a clinical trial using data from real patientsResearchers used real-world clinical data to attempt to emulate a randomized controlled trial testing the effectiveness of two blood thinners, apixaban and warfarin, to prevent stroke in patients with non-valvular atrial fibrillation.
Read more »